Find a study
Browse recruiting studies near you — free to check, always your choice.
8 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Eczema / atopic dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
Studying how dupilumab affects immune cells in eczema skin
📍 University of California, San Francisco · San Francisco, CA · Get directions →
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
- Eczema / atopic dermatitis
Dupilumab De-escalation in Pediatric Atopic Dermatitis
Testing whether stopping or lowering eczema treatment works for kids
📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Eczema / atopic dermatitis
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Testing a medicine called lebrikizumab for long-term improvement in eczema
📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
- Eczema / atopic dermatitis
Ethnic Differences in Mechanisms of Action of Dupilumab
Studying how a common eczema treatment works differently by race
📍 University of Michigan · Ann Arbor, MI · Get directions →
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.
- Eczema / atopic dermatitis
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Testing how dupilumab affects sleep, itching, and body clock in children with moderate to severe
📍 Lurie Children's Hospital/Northwestern University · Chicago, IL · Get directions →
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
- Eczema / atopic dermatitis
Dupixent and Narrowband UVB for Atopic Dermatitis
Testing dupilumab plus narrowband UVB light for eczema over 24 weeks
📍 Eczema Treatment Center of New Jersey · East Windsor, NJ · Get directions →
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
- Type 2 diabetesFatty liver disease (NASH/MASH)
Quantifying Hepatic Mitochondrial Fluxes in Humans
Measuring liver energy activity in people with type 2 diabetes before and after 16 weeks of insulin
📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone